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Background/aim: We report the analysis of ketamine doses needed and the recovery times in pediatric oncology patients undergoing
repeated radiotherapy sessions.
Materials and methods: In a single-blind prospective study design, thirty-three pediatric patients undergoing radiotherapy due to
oncologic disorders received 2 mg/kg ketamine and 10 µg/kg atropine intravenously and the rescue drug to be administered was
ketamine at 0.5 mg/kg when the sedation level was inadequate. Total ketamine consumption, additional doses, and recovery time were
recorded.
Results: Data of 635 consecutive radiotherapy sessions were evaluated. There was no significant alteration in total ketamine consumption
required to complete the radiotherapy periods during consecutive procedures (P > 0.05). However, the recovery times started to decrease
by the fourth session (P = 0.02) and continued to decrease onwards during the whole study period (P = 0.001). The mean of the first
recovery time was 13.68 ± 3.99 min, whereas the mean of the last recovery time was 7.66 ± 6.35 min.
Conclusion: A requirement for an incremental increase in ketamine dose after subsequent administrations was not detected, despite
a significant decrease in recovery times being anticipated when ketamine is used repeatedly for sedative purposes in consecutive
radiotherapy sessions.
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1. Introduction
Ketamine has been a subject of debate in recent years due
to its illicit use in some parts of the world. However, in
regions with limited resources, it is still a very valuable
option. Ketamine was first publicized as a “battle field
anesthetic” and it still preserves its unique place in
pediatric anesthesia with features such as maintaining a
state of dissociated consciousness along with spontaneous
breathing, intact laryngeal reflexes, and hemodynamic
stability (1). For anesthesiologists who are in the “battle
field” of anesthetic management every day, ketamine
provides a safety zone for sedated but spontaneously
ventilated children, especially in remote conditions such as
radiotherapy units where sedation is an essential practice
to keep children calm and motionless (2). However, there
has been disagreement about the ketamine doses needed
for a continuous and steady level of sedation during
repeated radiotherapy sessions in children. A tendency to
tolerance occurrence to ketamine has been claimed when
it is used in a repetitive manner and the opposite has also
been reported (3–5). The current literature also suggests

that N-methyl-D-aspartate (NMDA) receptor antagonists
themselves have tolerance-preventive effects and may
inhibit tolerance during long-term sedative and opioid
administration (6,7).
Any alteration in drug requirement to maintain
therapeutic or targeted effects has always been an issue
of interest for clinicians when repeat doses of any agent
are used. In this paper, we report the analysis of ketamine
doses needed and the recovery times in pediatric oncology
patients undergoing repeated radiotherapy sessions. This
paper may also add some more recent information for the
use of ketamine where circumstances limit the anesthetic
options.
2. Materials and methods
After approval from the Başkent University School of
Medicine’s Ethics and Research Committee (KA09/247)
and informed consent of the patients’ parents, 33 pediatric
patients undergoing radiotherapy due to oncologic
disorders were enrolled in this single-blind prospective
study. Patients younger than 1 year and older than 14 years;
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patients with cardiac, renal, or liver function abnormalities;
those who were already under sedative drug treatment or
allergic to the drugs to be used; and patients for whom the
study drugs were contraindicated were excluded from the
study.
Pediatric patients who were fasted for 6 h were
admitted to the preparation room, where they received
2 mg/kg ketamine and 10 µg/kg atropine intravenously.
All patients were monitored by electrocardiography,
noninvasive blood pressure, and pulse oximeter and a
closed-circuit camera system in the room. Sedation level
was assessed by the Children’s Hospital of Wisconsin
Sedation Scale and scores of 3 and 4 were accepted as
adequate for the procedure to start radiotherapy (8). If the
score exceeded 4, the rescue drug to be administered was
ketamine at 0.5 mg/kg. After the procedure, the patients
were observed until they achieved a score of 20 according
to the Vancouver Sedative Recovery Scale and this stage
was defined as “full recovery” to record the duration of
“recovery time”.
Patients’ demographic data (age, sex, weight), cancer
type, ASA physical status, and duration and total number
of radiotherapy sessions were noted. We included details
about patients’ pain according to the nurses’ notes (as
none, mild, moderate, or severe) in the files, since the
age group of the patients was not even suitable for Wong-

Baker Faces Pain Scale. Total ketamine consumption to
maintain the targeted sedation level during each session,
additional dose administration, and recovery time were
recorded. Adverse events such as apnea, laryngospasm,
bronchospasm, desaturation (SpO2 < 93%), respiratory
depression, bradycardia, sedation levels deeper or more
superficial than intended, excessive salivation, allergy,
nausea and vomiting, and need for emergency medication
were also noted after each session. The study drugs were
prepared, labeled, and administered by an anesthetist
according to the study protocol and data were recorded by
an anesthetist blind to the amount of the study drug used.
2.1. Statistical analysis
Data analysis was performed using SPSS 11.0 (SPSS Inc.,
Chicago, IL, USA). Data of the continuous variables were
presented as mean with standard deviation (SD) and
minimum and maximum values. Categorical data were
described in numbers or percentages as appropriate. The
Friedman ANOVA test was used for analysis of repeated
measures such as total ketamine consumption and recovery
times. P < 0.05 was considered as statistically significant.
3. Results
Data of 33 patients during 635 consecutive radiotherapy
sessions were evaluated. For one patient, radiotherapy was
stopped at the 5th session due to the critical condition of the

Table. Demographic data of the patients and duration and total number of
radiotherapy sessions (mean ± SD or n).
(n = 32)
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Age (years)

2.70 ± 0.84

Weight (kg)

13.02 ± 2.51

Sex (M/F)

19/13

ASA physical status (II/III)

31/1

Duration of radiotherapy sessions (min)

3.79 ± 1.77

Total number of sessions

19.68 ± 8.37

Cancer types of the patients (n)
Primary spinal glioma
Neuroblastoma
Atypical teratoid tumor
Leukemia
Rhabdomyosarcoma
Sacral bone tumor
Medulloblastoma
Neuroectodermal tumor

1
1
12
4
1
2
8
3

Pain levels according to nurse notes in the files (n)
None
Mild
Moderate
Severe

0
4
16
12
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patient. This case was excluded from the data analysis due
to paucity of the number of repeat sessions. The patients
who required benzodiazepines due to hallucinations and
restlessness were also excluded from the study so as not

to intervene with the sole assessment of ketamine use.
Demographic data of the patients included and duration,
total number of radiotherapy sessions, cancer type, and
pain assessment are presented in the Table.
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Figure 1. Total ketamine consumption required to complete the consecutive radiotherapy sessions.
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Figure 2. The recovery times after each consecutive radiotherapy session.
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Mean ketamine consumption at the first session
and the last session was 25.8 ± 14.5 mg and 25.4 ± 10.3
mg, respectively. There was no significant alteration in
total ketamine consumption required to complete the
radiotherapy periods during consecutive procedures (P >
0.05) (Figure 1). However, the recovery times started to
decrease by the fourth session (P = 0.02) and continued to
decrease onwards during the whole study period (P = 0.001)
(Figure 2). The mean of the first recovery time was 13.68 ±
3.99 min, whereas the mean of the last recovery time was
7.66 ± 6.35 min. The patients required additional ketamine
administration 54 times in 47 of 635 sessions (7.4%).
One patient in one session experienced transient
desaturation (SpO2: 90%), which was resolved with a
jaw-thrust maneuver in less than 2 min (the approximate
duration we approached the patient). He also had coughing
and needed repositioning and aspiration of secretions.
Another patient developed a mild allergic reaction with
cutaneous manifestations to atropine.
4. Discussion
In this study, we evaluated ketamine doses needed and
the recovery times during repeated radiotherapy sessions
in pediatric oncology patients. There was no significant
alteration in total ketamine consumption required to
complete the radiotherapy periods during consecutive
procedures; however, the recovery times started to
decrease by the fourth session and continued to decrease
onwards during the whole study period.
Efficient sedation with an absolute motionless state
and intact airway is essential during radiotherapy sessions
where the treated child and the anesthesia team have
been isolated from each other. These requirements lead
anesthetists to convey a sedation plan providing a similar
sedated state and a recovery profile even after many
numbers of repeated procedures such as radiotherapy
sessions (9). However, repeat sessions may cause
tolerance to the sedative agent used (10,11). Tolerance is
a challenging situation that physicians often encounter
during opioid use in clinical practice. The severity and
duration of the stimulus as well as pharmacokinetic and
pharmacodynamic alterations have been suspected for
development of tolerance to the therapeutic action of
drugs.
Ketamine has been a preferable anesthetic/analgesic
drug with its predictable sedation and recovery features
for diagnostic and therapeutic procedures in children
outside the operating room, such as in radiotherapy
units (12). Due to many receptor interactions, ketamine’s
unique properties are not limited to sedation and
analgesia; it is also efficient in maintaining the airway and
stable hemodynamics along with antihyperalgesic and
antiproinflammatory effects (1). Ketamine anesthesia has
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been reported to be related to increased radiosensitivity of
tumors (13). This may also prove that ketamine would be
more beneficial during radiotherapy. However, ketamine
may also raise a concern for increased dose requirements
or insufficient sedation levels and/or durations after
repeat administrations, although ketamine itself has been
suggested to play a tolerance-preventive role for opioids
during sedation in pediatric intensive care units (1,11).
Since there is no real pain experience or invasive
stimulus during radiotherapy sessions, the main aim
of ketamine-induced sedation is to preserve a steady
“dissociated” state in children. In this study, sufficient
sedation level and duration were achieved without a need
for an increase in initial ketamine dose or additional
drug administrations. The expected recovery time after
2 mg/kg ketamine was more than 15 min (12), but in
our study the recovery time decreased by approximately
50% after repeat sessions at a rate higher than in previous
reports (14). This may be interpreted as a decrease in the
dissociation period of the thalamus and the limbic system,
which basically enables the sedative effect of ketamine via
NMDA receptors. Upregulated or desensitized NMDA
receptors may hypothetically be responsible for the limited
duration of desynchronization of the thalamus and limbic
system after recurrent exposure to the drug. If there has
been a strong stimulus, such as pain in burn patients
who also undergo repeat ketamine-induced sedation
sessions for dressing changes, tolerance occurrence may
become more explicit by stimulation of miscellaneous
receptors, which may cause a noticeable tolerance-like
response in subjects (5,14). However, lack of an ongoing
strong procedural stimulation during radiotherapy
sessions lessens the anticipation for the upregulation of
receptors. Thus, we may speculate that this tolerance-like
effect depends more on a pharmacokinetic mechanism
than a pharmacodynamic one. Besides, after repeated
administrations, hepatic metabolism-based alterations in
the pharmacokinetics of ketamine were shown to decrease
circulating and brain levels of the drug and its active
metabolites and increase inactive oxidation metabolites,
thus resulting in a more rapid recovery (15).
The first limitation of our study may be the ketamine
dose regimen, which may be considered as a flaw in the
methodology. Although this dose was not very small, our
initial intention was to cover all procedures, even with
planning sessions, which require more time. However,
eventless procedural periods and acceptable recovery
durations allowed us to continue with this dosing.
Another reason to choose ketamine at a higher dose was
that most of the patients already had painful tumors,
which required some pain relief for positioning. Another
limitation was the brief duration of the sessions to detect
a need for dose increase to cover the therapy duration in
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each consecutive session. Any need for increased doses
could have been observed if the duration of the procedure
was long enough for ketamine’s sedative effect to disappear
during the intervention. However, we tried to prevent
an unintentional and subjective tendency to change the
amount of drug used for the procedure by using a sedation
scale that clarifies the end-point for the level of sedation.
Thus, this allowed us to optimize and standardize the
amount of ketamine. In addition we tried to identify the
recovery time according to a recovery scale to assess the
time required for a similar recovery level in each child.

In conclusion, a requirement for an incremental
increase in ketamine dose after subsequent administrations
was not detected, despite a significant decrease in recovery
times being anticipated when ketamine is used repeatedly
for sedative purposes in consecutive radiotherapy sessions.
The cross-section of this procedural overview might be
reproduced with further larger studies.
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